Clinical use and future perspective of aptamers

Esawi, Ezaldeen; Nsairat, Hamdi; Mahmoud, Ismail Sami; Lafi, Zainab; Al-Kadash, Abdulfattah; Al-Ragheb, Bayan Abu; Ismail, Said I.; Alhaer, Walhan

doi:10.1016/b978-0-323-85881-6.00013-0

Cited by 4 publications

(1 citation statement)

References 194 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The systematic evolution of ligands can synthesize aptamers by exponential enrichment (SELEX) technology [46] and thio-modified either enzymatically or chemically later on. Thioaptamers-coated nanovectors are currently under development [47][48][49].…”

Section: Tissue Targetingmentioning

confidence: 99%

Controlled and Targeted Drug Delivery Using Smart Nanovectors

Salama

Salem

Mohamed³

2023

IJDDP

View full text Add to dashboard Cite

Review Controlled and Targeted Drug Delivery Using Smart Nanovectors Abou Bakr M. Salama 1,2, Yasmin Y. Salem 1,2, and Tamer M. A. Mohamed 1,3,4,5,6, * 1 Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY 40208, U.S.A. 2 Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt. 3 Envirome Institute, Centre for Cardiometabolic Sciences, Department of Medicine, University of Louisville, KY 40208, U.S.A. 4 Department of Bioengineering, Speed School of Engineering, University of Louisville, KY 40208, U.S.A. 5 Department of Pharmacology and Toxicology, University of Louisville, KY 40208, U.S.A. 6 Institute of Cardiovascular Sciences, University of Manchester M13 9PL, U.K. * Correspondence: tamer.mohamed@louisville.edu Received: 28 January 2023 Accepted: 23 February 2023 Published: 20 March 2023 Abstract: The conventional drug delivery systems have several limitations, such as the high frequency of administration, several off-target effects, and the need for tissue specificity. Recently, smart drug shuttles have emerged, and the nano applications provided a new opportunity for advancing the drug delivery system to become tissue targeted and decrease the frequency of administration. The recent development of nanovectors as drug carriers has gone through several steps of evolution that ended with the development of logic-embedded nanovectors. Here, we summarize the different types of nanovectors and their applications in various clinical situations, and finally, we spot the light on the future of this area of research.

show abstract

Section: Tissue Targetingmentioning

confidence: 99%

Controlled and Targeted Drug Delivery Using Smart Nanovectors

Salama

Salem

Mohamed³

2023

IJDDP

View full text Add to dashboard Cite

show abstract

Aptamers: ushering in new hopes in targeted glioblastoma therapy

Chatterjee,

Bhattacharya,

Kumari

et al. 2024

Journal of Drug Targeting

View full text Add to dashboard Cite

Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers

Mahjoubin-Tehran,

Rezaei,

Santos

et al. 2024

Lipids Health Dis

View full text Add to dashboard Cite

The degradation of low-density lipoprotein receptor (LDLR) is induced by proprotein convertase subtilisin/kexin type 9 (PCSK9), resulting in elevated plasma concentrations of LDL cholesterol. Therefore, inhibiting the interactions between PCSK9 and LDLR is a desirable therapeutic goal for managing hypercholesterolemia. Aptamers, which are RNA or single-stranded DNA sequences, can recognize their targets based on their secondary structure. Aptamers exhibit high selectivity and affinity for binding to target molecules. The systematic evolution of ligands by exponential enrichment (SELEX), a combination of biological approaches, is used to screen most aptamers in vitro. Due to their unique advantages, aptamers have garnered significant interest since their discovery and have found extensive applications in various fields. Aptamers have been increasingly utilized in the development of biosensors for sensitive detection of pathogens, analytes, toxins, drug residues, and malignant cells. Furthermore, similar to monoclonal antibodies, aptamers can serve as therapeutic tools. Unlike certain protein therapeutics, aptamers do not elicit antibody responses, and their modified sugars at the 2’-positions generally prevent toll-like receptor-mediated innate immune responses. The focus of this review is on aptamer-based targeting of PCSK9 and the application of aptamers both as biosensors and therapeutic agents.

show abstract

Clinical use and future perspective of aptamers

Cited by 4 publications

References 194 publications

Controlled and Targeted Drug Delivery Using Smart Nanovectors

Controlled and Targeted Drug Delivery Using Smart Nanovectors

Aptamers: ushering in new hopes in targeted glioblastoma therapy

Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers

Contact Info

Product

Resources

About